Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
February 10, 2025 Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for...
Pharmaceutical
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was...
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology...
Mustang Bio Announces Closing of $8 Million Public Offering
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Qu Biologics’ Immunomodulator Clears Senescence
BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs),...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) --...
New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All...
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs) Company remains on track to report...
Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools...
Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
- BCVA and CST Data from Sub-Group Analyses Provide Key Insights for Planned CLS-AX Phase 3 Trial Design -ALPHARETTA, Ga.,...
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will...
Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
WALTHAM, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc Elia, Chairman of the...
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial...
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the...
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY® (dextromethorphan HBr – bupropion HCl) Patent Litigation
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new...
Save the Date: Orion’s Capital Markets Day on 22 May 2025
ORION CORPORATION INVESTOR NEWS 10 FEBRUARY 2025 at 14.00 EET Save the Date: Orion’s Capital Markets Day on 22...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
ANTARES VISION GROUP SIGNS LANDMARK AGREEMENT WITH THE MINISTRY OF HEALTH OF GUINEA-BISSAU
BRESCIA, Italy, Feb. 10, 2025 /PRNewswire/ -- Antares Vision Group, an Italian multinational leading provider in Track & Trace systems and...
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne
Dublin, Ireland, and Mumbai, India and London, United Kingdom--(Newsfile Corp. - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN)...